帝王会所

Resilient Medical Corp., developer and manufacturer of a novel implantable medical device that can reduce risks and ease healing for breast cancer patients, has graduated from the highly competitive JumpStart Trailblazer HealthTech Accelerator. Based in Cleveland, the program is a dedicated platform for 帝王会所鈥檚 health care startups, offering targeted support and critical resources to fuel innovation and prepare startups for venture capital investment.

鈥淭he HealthTech Accelerator is designed to help participants level up,鈥� said Kaleigh Gallagher, vice president of Tech Services and Network Management, at JumpStart, an entrepreneur support organization. 鈥淭hey get a deep dive into regulatory, clinical, reimbursement and commercialization strategies. This includes quantifying clinical and economic potential and building a roadmap for commercialization as preparation to raise capital, navigate the regulatory path and demonstrate commercial value.鈥�

Resilient is commercializing its BravoTM device, which will support soft tissue surgical repair, with long-term use aimed at addressing the invasiveness and trauma associated with lumpectomies. This means a smoother and less distressing recovery for breast cancer patients -- and overall improved cosmetic and mental health.

CEO and Founder Andrew Weems explained that while lumpectomies present fewer complications than mastectomies, including lower patient risk, cost, and shorter surgical times, they often neglect patient healing and cosmetic restoration.

鈥淭he current standard for treating lumpectomy patients involves closing the surgical site and allowing the resulting void to heal naturally, without additional support,鈥� he said. 鈥淧atients face risks such as painful and debilitating breast tissue collapse, as there are no implantable support devices available.鈥�

The only device of its kind, the Bravo offers three significant benefits: First, thanks to its 3D mesh structure, the Bravo eliminates the need for follow-up cosmetic reconstruction because it naturally integrates with the patient鈥檚 tissue. It also dissolves within about 12-18 months, so no additional procedures are needed. Finally, the Bravo also serves as a radiocontrast marker for post-operative adjuvant therapies, which are common in most breast cancer lumpectomy cases.

Jumpstart Executive in Residence Gary Smith said Weems is guiding Resilient to successful commercialization and impressive growth.

鈥淎ndrew harnessed key resources from Trailblazer program to enhance the company鈥檚 product development, pre-clinical testing, reimbursement, regulatory and go to market strategies,鈥� Smith said. 鈥淚鈥檓 confident Andrew is guiding Resilient to successful commercialization and impressive growth.鈥�

Resilient is a client of the 帝王会所 Innovation Center (IC), a tech startup incubator that supported the HealthTech Accelerator application. Venture organization TechGrowth 帝王会所 (TGO), which provides services, talent development and investment to companies that qualify, is the company鈥檚 lead investor.

Weems said the IC was a key component of being accepted to the program.

鈥淲e connected to Jumpstart because the IC generously guides their clients, and we were successful in part because of the IC team's engagement,鈥� he said. 鈥漈hey worked with us from the initial application process through the interview, including feedback and coaching during our final presentation prep.鈥�

As part of the Accelerator, Resilient successfully pitched the Bravo to a range of healthcare stakeholders, including physicians, patients, health systems, payers and commercial partners. He gained capital and is proceeding toward a clinical trial.

IC Executive Coach Colleen Carow, who helped Weems apply to the accelerator, cited Resilient鈥檚 acceptance as an exciting example of client success.

鈥淛umpstart's selection of Resilient Medical validates their business 鈥� and proves the company鈥檚 value. We can鈥檛 wait to see their growth,鈥� she said.